196 related articles for article (PubMed ID: 34620124)
1. Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials.
Gamper EM; Musoro JZ; Coens C; Stelmes JJ; Falato C; Groenvold M; Velikova G; Cocks K; Flechtner HH; King MT; Bottomley A;
BMC Cancer; 2021 Oct; 21(1):1083. PubMed ID: 34620124
[TBL] [Abstract][Full Text] [Related]
2. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
[TBL] [Abstract][Full Text] [Related]
3. Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.
Musoro JZ; Bottomley A; Coens C; Eggermont AM; King MT; Cocks K; Sprangers MA; Groenvold M; Velikova G; Flechtner HH; Brandberg Y;
Eur J Cancer; 2018 Nov; 104():169-181. PubMed ID: 30359910
[TBL] [Abstract][Full Text] [Related]
4. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.
Dirven L; Musoro JZ; Coens C; Reijneveld JC; Taphoorn MJB; Boele FW; Groenvold M; van den Bent MJ; Stupp R; Velikova G; Cocks K; Sprangers MAG; King MT; Flechtner HH; Bottomley A
Neuro Oncol; 2021 Aug; 23(8):1327-1336. PubMed ID: 33598685
[TBL] [Abstract][Full Text] [Related]
5. Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer.
Musoro JZ; Coens C; Fiteni F; Katarzyna P; Cardoso F; Russell NS; King MT; Cocks K; Sprangers MA; Groenvold M; Velikova G; Flechtner HH; Bottomley A;
JNCI Cancer Spectr; 2019 Sep; 3(3):pkz037. PubMed ID: 32328553
[TBL] [Abstract][Full Text] [Related]
6. Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy.
Musoro JZ; Sodergren SC; Coens C; Pochesci A; Terada M; King MT; Sprangers MAG; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
Colorectal Dis; 2020 Dec; 22(12):2278-2287. PubMed ID: 32767619
[TBL] [Abstract][Full Text] [Related]
7. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types.
Musoro JZ; Coens C; Sprangers MAG; Brandberg Y; Groenvold M; Flechtner HH; Cocks K; Velikova G; Dirven L; Greimel E; Singer S; Pogoda K; Gamper EM; Sodergren SC; Eggermont A; Koller M; Reijneveld JC; Taphoorn MJB; King MT; Bottomley A;
Eur J Cancer; 2023 Jul; 188():171-182. PubMed ID: 37257278
[TBL] [Abstract][Full Text] [Related]
8. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer.
Musoro JZ; Coens C; Singer S; Tribius S; Oosting SF; Groenvold M; Simon C; Machiels JP; Grégoire V; Velikova G; Cocks K; Sprangers MAG; King MT; Bottomley A;
Head Neck; 2020 Nov; 42(11):3141-3152. PubMed ID: 32627261
[TBL] [Abstract][Full Text] [Related]
9. Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials.
Koller M; Musoro JZ; Tomaszewski K; Coens C; King MT; Sprangers MAG; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A
Lung Cancer; 2022 May; 167():65-72. PubMed ID: 35413526
[TBL] [Abstract][Full Text] [Related]
10. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials.
Maringwa JT; Quinten C; King M; Ringash J; Osoba D; Coens C; Martinelli F; Vercauteren J; Cleeland CS; Flechtner H; Gotay C; Greimel E; Taphoorn MJ; Reeve BB; Koch JS; Weis J; Smit EF; van Meerbeeck JP; Bottomley A;
Support Care Cancer; 2011 Nov; 19(11):1753-60. PubMed ID: 20886240
[TBL] [Abstract][Full Text] [Related]
11. Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial.
Kawahara T; Taira N; Shiroiwa T; Hagiwara Y; Fukuda T; Uemura Y; Mukai H
Qual Life Res; 2022 Jun; 31(6):1829-1836. PubMed ID: 34982354
[TBL] [Abstract][Full Text] [Related]
12. Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol.
Musoro ZJ; Hamel JF; Ediebah DE; Cocks K; King MT; Groenvold M; Sprangers MAG; Brandberg Y; Velikova G; Maringwa J; Flechtner HH; Bottomley A; Coens C;
BMJ Open; 2018 Jan; 8(1):e019117. PubMed ID: 29326191
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma.
Reni M; Braverman J; Hendifar A; Li CP; Macarulla T; Oh DY; Riess H; Tempero M; Lu B; Marcus J; Joshi N; Botteman M; Dueck AC
Ann Surg Oncol; 2021 Nov; 28(12):7545-7554. PubMed ID: 33813673
[TBL] [Abstract][Full Text] [Related]
16. The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer.
Rodrigues G; Bezjak A; Osoba D; Catton P; Tsuji D; Taylor D; Warde P
Qual Life Res; 2004 Sep; 13(7):1235-46. PubMed ID: 15473502
[TBL] [Abstract][Full Text] [Related]
17. Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer.
Bedard G; Zeng L; Zhang L; Lauzon N; Holden L; Tsao M; Danjoux C; Barnes E; Sahgal A; Poon M; Chow E
Asia Pac J Clin Oncol; 2014 Jun; 10(2):109-17. PubMed ID: 23551530
[TBL] [Abstract][Full Text] [Related]
18. Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in ALTA-1L Trial.
Beaumont JL; Lin HM; Goodman E; Yu H; Geiger A; Hudgens S
Value Health; 2024 Feb; 27(2):182-189. PubMed ID: 37951539
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
20. Updated normative data for the EORTC QLQ-C30 in the general Dutch population by age and sex: a cross-sectional panel research study.
de Ligt KM; Aaronson NK; Liegl G; Nolte S;
Qual Life Res; 2023 Sep; 32(9):2477-2487. PubMed ID: 37031427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
